eltanexor
Selected indexed studies
- Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents. (J Hematol Oncol, 2022) [PMID:35922861]
- Eltanexor Effectively Reduces Viability of Glioblastoma and Glioblastoma Stem-Like Cells at Nano-Molar Concentrations and Sensitizes to Radiotherapy and Temozolomide. (Biomedicines, 2022) [PMID:36140245]
- A Novel Approach for Glioblastoma Treatment by Combining Apoptosis Inducers (TMZ, MTX, and Cytarabine) with E.V.A. (Eltanexor, Venetoclax, and A1210477) Inhibiting XPO1, Bcl-2, and Mcl-1. (Cells, 2024) [PMID:38607071]
_Worker-drafted node — pending editorial review._
Connections
eltanexor is a side effect of
Sources
- Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents. (2022) pubmed
- Eltanexor Effectively Reduces Viability of Glioblastoma and Glioblastoma Stem-Like Cells at Nano-Molar Concentrations and Sensitizes to Radiotherapy and Temozolomide. (2022) pubmed
- A Novel Approach for Glioblastoma Treatment by Combining Apoptosis Inducers (TMZ, MTX, and Cytarabine) with E.V.A. (Eltanexor, Venetoclax, and A1210477) Inhibiting XPO1, Bcl-2, and Mcl-1. (2024) pubmed
- The XPO1 Inhibitor Eltanexor Modulates the Wnt/β-Catenin Signaling Pathway to Reduce Colorectal Cancer Tumorigenesis. (2025) pubmed
- Nuclear Export Inhibitors Selinexor (KPT-330) and Eltanexor (KPT-8602) Provide a Novel Therapy to Reduce Tumor Growth by Induction of PANoptosis. (2023) pubmed
- Altered RNA export by SF3B1 mutants confers sensitivity to nuclear export inhibition. (2024) pubmed
- XPO1-dependency of DEK::NUP214 leukemia. (2025) pubmed
- The Second-Generation XPO1 Inhibitor Eltanexor Inhibits Human Cytomegalovirus (HCMV) Replication and Promotes Type I Interferon Response. (2021) pubmed
- DEK::NUP214 acts as an XPO1-dependent transcriptional activator of essential leukemia genes. (2025) pubmed
- The nuclear export protein exportin-1 in solid malignant tumours: From biology to clinical trials. (2024) pubmed